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Clinical evidence for parkinsonism may accompany Amyotrophic Lateral Sclerosis with a frequency ranging
from 5% to 17%. The concurrence of Amyotrophic Lateral Sclerosis and Parkinson's disease, outside the
known Guam and Kii Peninsula foci, is instead rare, but this raises the possibility of a common pathogenesis.
Clinically this complex presents with a levodopa-responsive parkinsonism and Amyotrophic Lateral Sclerosis
and has been termed Brait–Fahn–Schwartz disease.
Here we describe two patients with this uncommon neurodegenerative complex. Both presented with
Parkinson disease and progressed to a full blown Amyotrophic Lateral Sclerosis. We further suggest that
the association of Parkinson disease and Amyotrophic Lateral Sclerosis represents a distinct nosological enti-
ty, which should be kept separated from extrapyramidal signs and symptoms that may occur in Amyotrophic
Lateral Sclerosis.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
Extrapyramidal signs and symptoms due to nigrostriatal dysfunction
have been reported in patients with Amyotrophic Lateral Sclerosis (ALS)
[1–5]. However, outside the known ALS-Parkinson-Dementia complex
(ALS-PD) of the Guam and Kii Peninsula of Japan, the comorbidity of
Parkinson's disease and ALS is rare. This uncommon neurodegenerative
complex was ﬁrst described by Brait et al. [6]. The Parkinson's disease-
ALS complex (also termed with the eponym Brait–Fahn–Schwartz dis-
ease [4]) clinically presents itself with a levodopa-responsive parkin-
sonism followed by ALS, and can either be sporadic or familial [6–8].
Here, we report the clinical, laboratory and imaging studies of two
patients with idiopathic Parkinson's disease and ALS, and discuss the
nosologic and pathogenic implications of these two rarely overlapping
neurodegenerative disorders.
2. Case reports
The ﬁrst patient (A) was a 55 year-old woman with a six-month
history of resting tremor and cogwheel rigidity of her right hand
and arm and amoderate bradykinesia; her medical and genetic history
was negative. Familial history for extrapyramidal disorders was also
negative. The diagnostic workup was performed in another hospital
and a diagnosis of Parkinson's disease (PD) was made, based on the
clinical presentation and a good response to a levodopa load. Other
causes of parkinsonism were excluded.
She started a therapy with pramipexole and levodopa, with a sig-
niﬁcant improvement in her extrapyramidal symptoms and signs.
About one year after the diagnosis of PD, she began to complain of
weakness in her right lower limb. A right foot drop appeared. She
was referred to our Hospital. Neurological examination showed mus-
cle atrophy and weakness with spastic rigidity in the lower limbs,
more pronounced in the right leg. A moderate muscle atrophy was
noted in both hands and arms. Fasciculations were clinically evident
in the trunk and both upper limbs. Bilateral hyperactive deep tendon
reﬂexes, Hoffman's and Babinski's signs were present.
Mini Mental State Examination (MMSE) scored 30/30. Extensive
biochemical laboratory investigations were negative. Electromyogra-
phy revealed a neurogenic pattern of denervation with ﬁbrillations
and positive sharp waves in the four limbs. MRI of the brain showed
only a mild cortical atrophy while SPECT analysis with 123I-Ioﬂupane
revealed a bilateral reduced (≈−45%) striatal uptake (Fig. 1). Genetic
screening for SOD1, TDP-43, C9orf 72, FUS, angiogenin, Park-1,
Park-2, Park-6 and Park-7 (DJ-1) mutations was negative.
A diagnosis of ALS, according to El-Escorial-revised criteria [9],
which involves degeneration of the upper and lower motor neurons,
was made and riluzole was started. While the parkinsonian symptoms
continued to be controlled by the therapy, muscle atrophy and weak-
ness worsened and the patient six months later became wheel-chair
bound. Respiratory insufﬁciency ensued two years after ALS onset. A
non-invasive ventilation was started, but the patient died after few
months because of acute respiratory failure.
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The second patient (B) is a 69-year-old man with a two-year his-
tory of bradykinesia and resting tremor of his left hand, which
progressed to the right hand. Familial history for extrapyramidal dis-
orders was negative. He was diagnosed with PD in another hospital.
The diagnostic workup allowed exclusion of other causes of parkin-
sonism. A therapy with low-doses of levodopa was started which
led to a signiﬁcant improvement of the bradikynesia and, to a less ex-
tent, of the resting tremor. Sixteen months later, weakness and mus-
cle atrophy of upper limbs appeared, which were more disabling in
the left hand. As the patient is left-handed, this led to a marked difﬁ-
culty in opening bottles, eating or dressing himself: as a parkinsonian
patient he had never experienced those symptoms. During the fol-
lowing months, weakness and muscle atrophy worsened and fascicu-
lations in the upper limb were noted. He was thus referred to our
Center for evaluation.
The neurological examination the patient was hypomimic. Posture
was slightly camptocormic with trunk rigidity and minimal shufﬂing
gait. Moderate cogwheel rigidity and tremor (mixed, postural and rest-
ing) were present in the left hand. He showed a mild dysphagia and dys-
arthria. The tongue was atrophic with fasciculations. Weakness and
muscle atrophy with frequent fasciculations were detected bilaterally in
the shoulder girdles and upper limbs. Tendon reﬂexes were brisk in the
upper limbs, with the presence of the Hoffmann sign. In the lower limbs
only a very mild atrophy was evident with increased tendon reﬂexes
and a moderate rigidity. Coordination and all sensory modalities were
normal. MMSE scored 28/30. The biochemical workup, which included
a cerebrospinal ﬂuid analysis, was negative. EMG showed widespread
denervation in the four limbs and tongue. Brain MRI of documented a
mild cortical atrophy. SPECT analysis 123I-Ioﬂupane demonstrated a
bilateral reduced (−35%) striatal uptake. This patient underwent genetic
screening for SOD1, TDP-43, C9orf72, FUS, angiogenin, Park-1, Park-2,
Park-6, Park-7 (DJ-1) mutations which was negative. A diagnosis of
Parkinson disease with clinically-probable ALS was made [9]. He contin-
ued the levodopa therapy and riluzole was added with a transient im-
provement of the resting tremor. The clinical course was however
progressive and now the patient is wheel-chair bound and fed through
a PEG device.
3. Discussion
We have presented two patients with an idiopathic Parkinson's
disease (PD) who later, in the course of their disease, developed
Amyotrophic Lateral Sclerosis. This neurodegenerative complex, in-
deed very rare, has been given the eponym of Brait–Fahn–Schwartz
disease [4,6]. Growing evidence suggests that this association is in
fact not coincidental, as it may share a common pathogenic basis
[4,7].
Parkinsonism may associate with motor neuron disease (MND) in
various neurodegenerative conditions, such asmultiple system atrophy,
hereditary spastic paraplegia, SCAs, fronto-temporal lobar degeneration.
In these disorders, MND usually manifests as amyotrophy, expression of
lower motor neuron degeneration.
Symptoms and signs of parkinsonism have also been described in
ALS [2,4,6,10–12], with a frequency ranging from 5% to 17% [12–14].
Fig. 1. MRI and 123I-Ioﬂupane SPECT of the patient A. Axial T2-weigthed (A) and FLAIR coronal (B) MRI show a mild cortical atrophy with no altered signals in the white matter.
123I-Ioﬂupane SPECT of the basal ganglia demonstrated a bilateral reduced striatal uptake, with a slight prevalence on the left side (C). A 123I-Ioﬂupane SPECT image of an unrelated
age-matched control is shown for comparison (D).
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ALS however is a distinct MND, which involves both upper and lower
motor neurons-related symptoms and signs, and it shows a steadily
clinical progression. When associated to ALS, parkinsonian signs and
symptoms have been referred to as slowness of gait with postural in-
stability, rigidity and bradykinesia with an overall poor response to
levodopa therapy [11,15]. In a large series of ALS patients, 39 cases
(17%) with prevalent stiffness were identiﬁed in which extrapyrami-
dal features of rigidity and postural instability were found to be high-
ly correlated with the pyramidal signs [12]. This association has been
recently challenged, as no correlation was found between clinical rat-
ing scales assessing bradykinesia and postural instability and the de-
gree of nigrostriatal impairment on 123I-Ioﬂupane scintigraphy in
patients with upper motor neuron dominant ALS [16].
There is evidence, however, of a decreased striatal dopaminergic
function in ALS [5,14,17]. Furthermore, necropsy studies have shown
neuronal loss in the substantia nigra and globus pallidus of ALS patients
[18,19]. This strongly suggests that the extrapyramidal system is actual-
ly involved in this neurodegenerative disease, and this raises the ques-
tion as to whether ALS should be included among the multisystem
disorders.
A dominant axial rigidity with bradykinesia and a lack of pharmaco-
logical response to levodopa are the most striking features seen in ALS
patients with parkinsonism [4,11,15]. Our two unrelated Brait–Fahn–
Shwartz disease (i.e., PD–ALS complex) patients were cognitively nor-
mal and showed clinical and imaging features consistent with a clinical
diagnosis of PD, with a good response to dopaminergic therapy and a
clear-cut clinical progression of the extrapyramidal symptoms before
the appearance of the upper and lower motor neuron degeneration
[4,6]. Recently, a PD–ALS syndrome with dementia has been described
to be associated with mutations of DJ-1 (Park-7), a gene causing early-
onset PD [8]. This oncogene protein is widely expressed in CNS and it
plays a neuroprotective role mitochondria-mediated against oxidative
stress in PD and ALS models [20,21]. Thus, there is increasing evidence
that PD and ALS may share a common pathogenesis in a subgroup of
patients.
In conclusion, these two cases of Brait–Fahn–Schwartz disease re-
inforce the evidence that the association of PD and ALS might repre-
sent a distinct pathological entity [4,8]. This should be separated
from the extrapyramidal signs and symptoms that may appear in
ALS. The positive and persistent response to dopaminergic drug ther-
apy and the sequence by which progressive parkinsonian symptoms
and signs precede the appearance of ALS represent the two strong
clinical markers of this rare syndrome.
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